Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Public ClinicalTrials.gov record NCT02263508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of the Phase 1b part of the study are to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with previously untreated, unresectable, stage IIIB to IVM1c melanoma. The primary objective of Phase 3 are to evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded independent central review using modified Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) and overall survival (OS).
Study identification
- NCT ID
- NCT02263508
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 713 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2014 (Actual)
- Primary completion
- Mar 11, 2021 (Actual)
- Completion
- Mar 11, 2021 (Actual)
- Last update posted
- Nov 14, 2022
2014 – 2021
United States locations
- U.S. sites
- 41
- U.S. states
- 19
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35243 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Encinitas | California | 92024 | — |
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Riverside | California | 92505 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | San Francisco | California | 94117 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Baltimore | Maryland | 21237 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Fridley | Minnesota | 55432 | — |
| Research Site | St Louis | Missouri | 63110-1093 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Cincinnati | Ohio | 45209 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Murray | Utah | 84107 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
| Research Site | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 120 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02263508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02263508 live on ClinicalTrials.gov.